We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.20 | -0.75% | 26.30 | 344,453 | 16:35:15 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 26.00 | 26.60 | 26.90 | 26.50 | 26.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Med, Dental, Hosp Eq-whsl | 50.19M | 6.24M | 0.0138 | 19.28 | 120.24M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:42:27 | O | 132,792 | 26.3611 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 02/6/2025 | 07:00 | UK RNS | EKF Diagnostics Holdings PLC Total Voting Rights |
| 21/5/2025 | 21:51 | ALNC |  TRADING UPDATES: Revolution Beauty shares up as receives bid approach |
| 21/5/2025 | 07:00 | UK RNS | EKF Diagnostics Holdings PLC Additional Share Buyback Programme |
| 20/5/2025 | 22:01 | ALNC | TRADING UPDATES: Poolbeg upsizes fundraise amid strong investor demand |
| 20/5/2025 | 14:41 | UK RNS | EKF Diagnostics Holdings PLC Result of AGM and Voting Results |
| 20/5/2025 | 07:00 | UK RNS | EKF Diagnostics Holdings PLC AGM Statement |
| 13/5/2025 | 07:00 | UK RNS | EKF Diagnostics Holdings PLC Share Buyback & Completion of Share Buyback.. |
| 09/5/2025 | 13:42 | UK RNS | EKF Diagnostics Holdings PLC Share Buyback |
| 08/5/2025 | 09:11 | UK RNS | EKF Diagnostics Holdings PLC Share Buyback |
| 06/5/2025 | 15:55 | UK RNS | EKF Diagnostics Holdings PLC Share Buyback |
Ekf Diagnostics (EKF) Share Charts1 Year Ekf Diagnostics Chart |
|
1 Month Ekf Diagnostics Chart |
Intraday Ekf Diagnostics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 05/6/2025 | 16:26 | EKF Diagnostics PLC - Cash generative, undervalued and primed for growth! | 296 |
| 23/3/2024 | 09:54 | EKFEREKA | - |
| 23/3/2024 | 09:18 | EKF Diagnostics for income and growth - A healthy, reliable combination! | 3,237 |
| 24/9/2020 | 22:56 | EKF Diagnostics - Growth by acquisition, expertise and special relationships | 1,376 |
| 27/7/2011 | 06:35 | EKF Diagnostics – Growth by acquisition, expert knowledge and special relationsh | 7 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 14/6/2025 09:20 by Ekf Diagnostics Daily Update Ekf Diagnostics Holdings Plc is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 26.50p.Ekf Diagnostics currently has 453,730,564 shares in issue. The market capitalisation of Ekf Diagnostics is £120,692,330. Ekf Diagnostics has a price to earnings ratio (PE ratio) of 19.28. This morning EKF shares opened at 26.50p |
Posted at 02/4/2025 22:27 by p1nkfish To take on Hemocue (the one to beat going forward), EKF need to address channels to the US market and accuracy if they want to address the Hospital side - dominated by Abbott/Siemens.Interestingly Hemocue, I believe, manufacture predominantly in Sweden and will be hit with a 20% tariff. They are already higher priced but do offer higher accuracy and have market acceptance. EKF could be hit with a 10% tariff out of the UK but if able to manufacture at their US site would avoid it all together and have a very decent cost advantage with less disruption. EKF's footprint spread may be a real advantage. Abbott/Siemens will dominate the Hospital demand, EKF might do very well in clinic and other non-hospital and especially where there are budget constraints. Well enough to make a big difference to EKF. If they can find a channel partner with reach it will help accelerate. Acquisitions look too pricey or already acquired. |
Posted at 25/3/2025 15:18 by cisk Not sure if any of you are attending the meeting today, but I urge you all to have these points in mind - my thought is that there is no way on earth shareholders should support a) share buybacks, or b) another acquisition - and here's why:1. buybacks: they've wasted at least $2.5m on them in the past (av price of 43p! for 9,000,000 shares) - $2.5m loss current share price (after todays bump) 2. Acquisitions - phew where to start here: - ADL cost $10m, sold for <$1m - Selah cost $36m, sold / written off for ZERO - Stanbio cost $25m, think they closed most of it, some parts kept Not to mention a lot of cash on Renalytix / Trellus, which given the existing share price must be worth very little now. And the whole fermentation thing - will it ever make money? So the best AND ONLY option they should be considering is reinstating the dividend and build out the existing business - growing organically. They have WASTED so many tens of millions over the years, what a shambles. Excuses after excuses. |
Posted at 07/2/2025 07:58 by wan I note Schroders reduced holding announcement yesterday. Has Schroder been the seller, and given that the share ticked up, are they done? Time will tell!I also note some EKF news - Transforming Healthcare with Seamless Point-of-Care Connectivity 31/01/2025 The healthcare industry is constantly evolving. One of the most exciting developments is how new technology integrates into everyday practices. From managing electronic medical records (EMRs) to connecting diagnostic devices, innovative solutions can help to make healthcare faster, more efficient, and patient-friendly. At EKF Diagnostics, we are simplifying healthcare data management with our point-of-care (POC) data management software, EKF Link. Let’s explore how integrations and tools like EKF Link can improve clinical workflow and ultimately enhance patient care. Full details - Interestingly, EKF previously reported that they were seeing increased interest from other players in utilising EKF Link. In my opinion, EKF Link is under appreciated in terms of augmenting opportunity. |
Posted at 03/12/2024 10:45 by wan I agree that the share price indicates a lack of positivity in the market, and that currently, there is nothing factored into the share price for improved growth prospects (some would argue justifiably). But given the guidance to date, is it also a case of no news is, sort of, good news? Time will tell!Obviously, progress and confirmation in 2025 is going to be pivotal, and my previous points was that the market clearly wants confirmation/clear evidence, hence my comments regarding the type of catalysts required for a rerating. And even though there is evidence (see further below) that EKF are addressing important markets with excellent growth prospects e.g. leading position in B-HB production, and not least their development of a 'dual' glucose/BHB test which is presumably a 'single/dual' test strip and separate reader, where to my mind there could be two potential applications - ip around the dual-analyte strip i.e. can that technology/applicati And perhaps overlooked, and again to my mind at least, this aspect (test development/and hopefully a positive update) should further improve the already strong relationships with the likes of Thermo Fisher, Cardinal Health, and Quidelortho in the 'existing' BHB business, and indeed beyond. Staying with Thermo: I note that a competitor (of sorts!) BHB reader product and the related strips have been discontinued by the Fisher Scientific Chanel, but importantly they direct you to an alternative product: EKF's Blood Glucose β-Ketone Strips @ $315 for a pack of 50 - One assumes that that will also be aided by the "significantly increased β-HB fermentation yield". JB stated that they will have feasibility completed on their new glucose/BHB test by Christmas, let's hope we get a positive update in early 2025 in that regard, and hopefully more (they have missed before with regard to test in development). |
Posted at 22/11/2024 09:47 by wan Clearly there are sellers of EFK shares.However, I personally don't think there is anything wrong fundamentally, aside from the obvious selling pressure which appears to be more about sentiment and factors affecting the market as a whole, as opposed to EKF's prospects (unless I am missing something!). Important questions are: where could the catalysts come from? And will any catalysts change sellers perspectives, or just delay their intentions (merely taking advantage of an improved price/demand)? Clearly there is an overhang, so one catalyst could be when the seller/s are finished, and/or demand outweighs the seller (clearly buyers appear to ultimately need more than just EKF appears cheap!). EKF is cash generative, so one potential catalyst would be the reinstatement of a dividend policy, which without much doubt would be well received, especially given the stickiness of inflation and the prospect of interest rates remaining higher than envisaged. Currently, there is nothing factored into the share price for improved growth prospects, so a confirmation that growth is being both delivered and forecasted would, on its own, be well received. And even better if that was backed up with an emerging or reinstated dividend policy! On a question as to the correct strategy being in place at South Bend, JB stated that he was personally tired with saying we haven't delivered on what we should have from South Bend, but countered that the South Bend business hasn't seen any downside and that the business was very strong with considerable upside going forwards. However, given that South Bend has underwhelmed to date, the market is not rewarding anything for the potential, which is fair enough......but may change if the potential and considerable upside actually starts being delivered and realised! A positive update in this regard would, at the very least, also improve sentiment. Additional enzymes that are held in EKF storage, along with EKF's existing enzymes and IP, could apparently deliver a new EKF glucose/BHB test. Management has stated that the new test will be very complimentary to EKF's established lab-based BHB testing, and also stated that EKF will have feasibility completed on their new glucose/BHB test by Christmas. I believe that a positive update in this regard would also be well received, but would need something beyond "we think this works" etc to effectively move the needle, such as a technology breakthrough/acceler There is more to add to the list, so please feel free to add potential, realistic upside or downside catalysts. |
Posted at 21/9/2024 09:19 by wan Looking forward, and coming back to Presentation points worthy of particular mention:EKF's connectivity platform. EKF Link is EKF's in-house developed data and device management system, which is test agnostic and can be used on any platform beyond EKF's analysers. Its adaptability and ease of use make it a valuable connectivity addition to any healthcare setting, including hospitals, laboratories, blood banks, pharmacies, and general practitioners - What also caught my attention (at 36 mins in) is the fact that EKF Link is proving to be so popular that it is also driving enquiries beyond EKF's own point-of-care portfolio, with EKF receiving approaches from companies with 'approved' testing technologies where they haven't got the effective distribution channels that EKF has. The enquiries are not just about utilising EKF Link to provide important connectivity options, with EKF being asked if they would be interested in licensing the other companies products to sell through EKF's firmly established and 'differentiated' distribution channels, in turn providing further opportunities for growth. Subsequently, due to the success and as part of the pivot to a 'multiple' growth opportunities, EKF is looking to expand the connectivity opportunity by putting a commercial team behind EKF Link, driving growth and opening more doors to new opportunities. |
Posted at 05/9/2024 13:56 by smithie6 B-HBGLP-1 T1DM as I have posted before anyone posting loads of detailed technical mumbo jumbo, it is surely a complete waste of time for 80-99% of readers who surely have no idea the possible benefit, or not, these things might have to the EKF share price. and the author seems to generally avoid ever indicating what impact on the eps or the share price these things like B-HB might have & that is what most of us are interested in. so, Wan's high tech posts are probably mostly all just water passing by under the bridge, unseen, unnoticed. imo anyway. |
Posted at 15/8/2024 09:35 by wan I am fully cognisant of what occurred in the past (which contain both good and bad elements), so these events are certainly not airbrushed out from my assessments.There is a fact that is perhaps overlooked by statements indicating EKF has gone sideways in terms of growth and potential: In 2019 EKF sold 74m+ Point-of-Care tests. In 2023 EKF sold 95m+ Point-of-care tests (80m in 2022), and are now likely to be knocking on the door of 100m+ tests sold (which could pique outside interest). That type of progress does not come easy and is not currently reflected in the share price, as perhaps indicated by the deep discount to the brokers recent 'upgraded' share price target of 39p. And put another way, a 40% premium bid would still only match the brokers target share price, which remains conservative and may be upgraded. And btw, in that upgrade, the broker commented that EKF is now showing clear evidence that the increased focus on core products is having a beneficial impact on gross margins, earnings growth and cash generation, building on the initial positive signs from Q1. |
Posted at 10/6/2024 11:06 by wan I am drawn to the recent acquisition of Point-of-Care player Lumira Dx by Roche for $295 million upfront and another cache of up to $55 million, which on its own effectively demonstrates the interest in point-of-care diagnostics.In its last set of recorded revenues, Lumira had $9.2 million in non-COVID sales in the first half of 2023, which equates to around £7m sterling. In 2023, EKF recorded non-Covid sales of £48.7m, with point-of-care recording £32.4m (excluding clinical chemistry and Covid related revenues), which is equivalent to a comparison of around £16m first half revenues compared to Lumira's £7m. (note that EBITDA for the first three months of the year is already showing a c.20% improvement on Q1 2023, and that 2024 will be a year of significant momentum in terms of both EBITDA margins and cash generation). Roche is paying a combined £275m sterling compared to EKF's current market cap of £133m sterling. I appreciate that Roche predominantly bought the technology and not the revenues per se, but it shines at least some light on the value of EKF's globally installed base, and the value of the embedded technology which is further demonstrated by EKF's growing recurring revenues (95 million individual test consumables in 2023). Importantly, EKF's point-of-care technology development is not standing still, which will no doubt be significantly augmented by EKF's new fermentation facility (in contrast to Lumira) e.g. developing and manufacturing enabling consumable diagnostic products (and not just for EKF, but also for medical diagnostics, pharmaceuticals, and industrial applications, facilitating transformative breakthroughs in healthcare and beyond). EKF are doing what Private Equity would do in terms of rationalisation and operational efficiency improvements, which gives pause for thought as to whether AIM is 'ultimately' the right place for listing EKF, or whether those measures and an AIM listing makes EKF an attractive acquisition target (surely it does at the current share price?), and indeed whether Harwood Capitals 29.169% holding will ensure EKF does not succumb to a lowball offer. EKF appears underappreciated (some would say deservedly), despite being debt free, cash generative, undervalued and primed for further growth in 2024. It will therefore be interesting to see whether there is anything beyond a technical pullback in the share price as the quieter summer season approaches, or whether the summer turns out to be an extended hunting season for acquiring UK stocks, with the possibility of EKF being on the menu! Please conduct your own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate. |
Posted at 23/3/2024 09:07 by wan EKF is a global diagnostics and biotechnology company manufacturing and delivering diagnostic technologies and biotechnology solutions that empower healthcare and medical providers to make informed clinical decisions through point-of-care testing and life sciences applications.After rationalisations and investments made over the last two years resulting in a simplified structure of two divisions, Point-of-Care and Life Sciences, EKF is now well placed to deliver sustainable growth and improved returns. In a buy recommended brokers note, Panmure Gordon said: “EKF looks circa 30% undervalued on the basis of the point of care division alone, encouraging progress with customers in the new fermentation facility offers the potential for further upside. Emerging from its transitional period EKF is well positioned for a return to more consistent performance and a strengthening cash position.” Singer Capital Markets broker note: EKF’s FY23 results are in line / slightly ahead of expectations. Growth drivers remain intact in both Point-of-Care and Life Sciences and, with a greater focus on core products, margins should continue to improve from here. This is key to supporting a re-rating and we see considerable value at current levels. With profit forecasts unchanged, we roll forwards our valuation to FY24 and increase our TP to 36p, reiterating our Buy recommendation. (full note available via Research Tree - It's perhaps somewhat underappreciated that EKF has a well-established and comprehensive base of installed Point-of-Care diagnostic users supported by high-quality global distribution channels. In 2023, EKF sold over 12,000 Point-of-Care analysers, resulting in the sale and manufacture of over 95 million individual test consumables. The installed base of diagnostic instruments is currently delivering guaranteed recurring revenues of £35-40m, and is set for further growth in 2024 and beyond (cue Panmure Gordon's point-of-care comment above). In Life Sciences, EKF has invested in a new facility with a full range of fermenters of different capacity, including increased downstream processing, offering contract fermentation services for clinically important enzymes and proteins. EKF Life Sciences is at the forefront of supporting global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver advancements in healthcare and medicine. Utilising its unique technical expertise, EKF Life Sciences uses precision microbial fermentation and advanced downstream processes to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications. Customer onboarding has commenced with several fermentation runs completed that will generate revenue in 2024 and will lead to further growth in 2024 as the new customers scale up. With a full range of fermenters of different capacity now online, EKF will look to scale up output throughout 2024 and to add additional customers throughout the current year. EKF are also in active discussions with new fermentation customers for development and scale-up opportunities to come on-line late 2024 and through to 2025. EKF's Outlook Statement: • Investment in our focused core products within Hematology, Diabetes and β-HB will drive further, sustainable growth • Strengthening relationships with key global partners and distribution channels to increase our existing market share in identified core product ranges • 2024 will see the completion of the rationalisation process, resulting in a streamlined core business portfolio, and expansion of fermentation offering • EKF is well placed to deliver growth and improved returns from the investments made over the last two years Presentation - Please conduct your own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
